US Supreme Court unanimously overturns Federal Circuit decision in Medtronic

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

US Supreme Court unanimously overturns Federal Circuit decision in Medtronic

The US Supreme Court has unanimously reversed the Federal Circuit decision in Medtronic v Boston Scientific, reinforcing the established rule that the patent owner bears the burden of proving that infringement has occurred

The ruling overturns a September 2012 decision by the Federal Circuit, which found that in cases where a licensee seeks a declaratory judgment against a patent holder, the licensee bears the burden of proof. The Federal Circuit reasoned that since Medtronic was asking a court to declare the products in question did not infringe, it should bear the burden of proving it was entitled to such relief.

But after hearing arguments in November last year, the Supreme Court unanimously ruled today that even in such cases, the patentee bears the burden of proof.

In its opinion, the Supreme Court quoted a decision in Precision Instrument Manufacturing v Automotive Maintenance Machin­ery: The public interest, of course, favours the maintenance of a well-functioning patent system. But the ‘public’ also has a ‘paramount interest in seeing that patent monopo­lies . . . are kept within their legitimate scope.'”

Justice Stephen Breyer, writing on behalf of all the justices, concluded: “The general public interest considerations are, at most, in balance. They do not favour a change in the ordinary rule imposing the burden of proving infringement upon the patentee.”

The dispute stems from 2007 claim that a device manufactured by Medtronic, known as a cardiac resynchronisation therapy, infringed patents owned by Mirowski Family Ventures, which licensed them to Boston Scientific. The parties had agreed that Medtronic would sub-license the patents and pay royalties on any new products it made which used the technology they covered.

But the parties disagreed on whether Medtronic’s CRT products used technology covered by the patents. The District Court for the District of Delaware found that the patents were valid and enforceable but that Medtronic did not violate them.

more from across site and SHARED ros bottom lb

More from across our site

As Marshall Gerstein celebrates its 70-year anniversary, Jeffrey Sharp, managing partner, reflects on lessons that shaped both his career and the firm’s success
News of two pharma deals involving Novo Nordisk and GSK and a loss for Open AI were also among the top talking points
Howard Hogan, IP partner at Gibson Dunn, says AI deepfakes are driving lawyers to rethink how IP protects creativity and innovation
Vivien Chan joins us for our ‘Women in IP’ series to discuss gender bias in the legal profession and why the business model followed by law firms leaves little room for women leaders
Partner Jeremy Hertzog explains how his team worked through a huge amount of disclosure from Adidas and what victory means for the firm
Evarist Kameja and Hadija Juma at Bowmans explain why a new law in Tanzania marks a significant shift in IP enforcement
In the wake of controversy surrounding Banksy’s recent London mural, AJ Park’s Thomas Huthwaite and Eloise Calder delve into the challenges street artists face in protecting their works and rights
Alex Levkin, founder of IPNote, discusses reshaping the filing industry through legal tech, and why practitioners’ advice should stretch beyond immediate legal needs
Cohausz & Florack, together with Krieger Mes & Graf von der Groeben, has taken action against Amazon on behalf of three VIA LA licensors
In the fourth episode of a podcast series celebrating the tenth anniversary of IP Inclusive, we discuss unconscious bias in the IP workplace and how to address it
Gift this article